Nixon Peabody Trust Co. Has $343,000 Stock Position in Johnson & Johnson (NYSE:JNJ)

Nixon Peabody Trust Co. trimmed its position in Johnson & Johnson (NYSE:JNJGet Rating) by 16.8% in the second quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 1,930 shares of the company’s stock after selling 390 shares during the quarter. Nixon Peabody Trust Co.’s holdings in Johnson & Johnson were worth $343,000 as of its most recent SEC filing.

A number of other hedge funds and other institutional investors have also recently added to or reduced their stakes in the company. RE Dickinson Investment Advisors LLC grew its position in shares of Johnson & Johnson by 163.3% during the 1st quarter. RE Dickinson Investment Advisors LLC now owns 158 shares of the company’s stock worth $28,000 after buying an additional 98 shares during the period. Advanced Research Investment Solutions LLC grew its position in shares of Johnson & Johnson by 200.0% during the 1st quarter. Advanced Research Investment Solutions LLC now owns 180 shares of the company’s stock worth $32,000 after buying an additional 120 shares during the period. Morton Brown Family Wealth LLC grew its position in shares of Johnson & Johnson by 78.0% during the 2nd quarter. Morton Brown Family Wealth LLC now owns 178 shares of the company’s stock worth $32,000 after buying an additional 78 shares during the period. Professional Financial Advisors LLC grew its position in shares of Johnson & Johnson by 47.9% during the 1st quarter. Professional Financial Advisors LLC now owns 210 shares of the company’s stock worth $37,000 after buying an additional 68 shares during the period. Finally, Goodman Advisory Group LLC acquired a new position in shares of Johnson & Johnson during the 2nd quarter worth about $39,000. 68.59% of the stock is currently owned by institutional investors and hedge funds.

Insider Transactions at Johnson & Johnson

In other news, insider William Hait sold 15,000 shares of the company’s stock in a transaction that occurred on Monday, October 24th. The stock was sold at an average price of $171.55, for a total transaction of $2,573,250.00. Following the sale, the insider now owns 80,236 shares in the company, valued at approximately $13,764,485.80. The sale was disclosed in a document filed with the SEC, which is available at the SEC website. In related news, VP Thibaut Mongon sold 35,246 shares of the stock in a transaction on Friday, November 4th. The stock was sold at an average price of $171.18, for a total value of $6,033,410.28. Following the sale, the vice president now owns 40,133 shares in the company, valued at approximately $6,869,966.94. The transaction was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Also, insider William Hait sold 15,000 shares of the stock in a transaction on Monday, October 24th. The shares were sold at an average price of $171.55, for a total value of $2,573,250.00. Following the completion of the sale, the insider now owns 80,236 shares in the company, valued at approximately $13,764,485.80. The disclosure for this sale can be found here. Insiders have sold a total of 212,646 shares of company stock worth $36,791,022 in the last 90 days. Corporate insiders own 0.35% of the company’s stock.

Johnson & Johnson Trading Up 0.1 %

NYSE JNJ opened at $177.01 on Friday. The stock has a market capitalization of $462.79 billion, a price-to-earnings ratio of 24.65, a PEG ratio of 3.50 and a beta of 0.57. The stock’s 50 day moving average price is $168.60 and its two-hundred day moving average price is $171.32. The company has a debt-to-equity ratio of 0.37, a quick ratio of 1.18 and a current ratio of 1.43. Johnson & Johnson has a 52 week low of $155.72 and a 52 week high of $186.69.

Johnson & Johnson (NYSE:JNJGet Rating) last released its earnings results on Tuesday, October 18th. The company reported $2.55 EPS for the quarter, beating the consensus estimate of $2.49 by $0.06. The firm had revenue of $23.79 billion for the quarter, compared to analysts’ expectations of $23.44 billion. Johnson & Johnson had a return on equity of 35.37% and a net margin of 19.95%. The business’s quarterly revenue was up 1.9% compared to the same quarter last year. During the same quarter in the previous year, the business posted $2.60 EPS. As a group, analysts anticipate that Johnson & Johnson will post 10.04 earnings per share for the current fiscal year.

Johnson & Johnson announced that its board has authorized a share repurchase plan on Wednesday, September 14th that allows the company to repurchase $5.00 billion in outstanding shares. This repurchase authorization allows the company to buy up to 1.2% of its stock through open market purchases. Stock repurchase plans are often an indication that the company’s management believes its shares are undervalued.

Johnson & Johnson Dividend Announcement

The business also recently disclosed a quarterly dividend, which will be paid on Tuesday, December 6th. Stockholders of record on Tuesday, November 22nd will be paid a dividend of $1.13 per share. This represents a $4.52 dividend on an annualized basis and a dividend yield of 2.55%. The ex-dividend date is Monday, November 21st. Johnson & Johnson’s dividend payout ratio is currently 62.95%.

Analysts Set New Price Targets

Several equities analysts have recently issued reports on JNJ shares. Atlantic Securities decreased their target price on Johnson & Johnson from $165.00 to $160.00 and set a “neutral” rating for the company in a research report on Wednesday, October 19th. Credit Suisse Group started coverage on Johnson & Johnson in a research report on Thursday, November 17th. They issued a “neutral” rating and a $170.00 price objective for the company. Sanford C. Bernstein decreased their price objective on Johnson & Johnson from $194.00 to $190.00 in a research report on Wednesday, October 19th. Morgan Stanley decreased their price objective on Johnson & Johnson from $174.00 to $170.00 and set an “equal weight” rating for the company in a research report on Wednesday, October 19th. Finally, Raymond James decreased their price objective on Johnson & Johnson from $192.00 to $185.00 and set an “outperform” rating for the company in a research report on Wednesday, October 19th. Seven equities research analysts have rated the stock with a hold rating, four have assigned a buy rating and one has issued a strong buy rating to the company. According to data from MarketBeat.com, the stock has an average rating of “Moderate Buy” and an average price target of $181.33.

Johnson & Johnson Company Profile

(Get Rating)

Johnson & Johnson, together with its subsidiaries, researches and develops, manufactures, and sells various products in the healthcare field worldwide. The company's Consumer Health segment offers baby care products under the JOHNSON'S and AVEENO Baby brands; oral care products under the LISTERINE brand; skin health/beauty products under the AVEENO, CLEAN & CLEAR, DR.

Further Reading

Institutional Ownership by Quarter for Johnson & Johnson (NYSE:JNJ)

Receive News & Ratings for Johnson & Johnson Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Johnson & Johnson and related companies with MarketBeat.com's FREE daily email newsletter.